Ketamine HCl Injection Syringes Recalled Due to Sterility Assurance Failure
Nephron Sterile Compounding Center is recalling Ketamine HCl Injection pre-filled syringes due to lack of assurance of sterility. The recall affects 30,745 syringes distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall for a sterility assurance failure. The hazard involves an injectable medication where sterility is critical to safety. The risk profile qualifies as 'High' under the rubric for risk-of-harm products.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Ketamine HCl Injection, USP 30 mg/3 mL pre-filled syringes. The recall affects approximately 30,745 syringes with Lot KH2002A (expiration 7/5/2022) distributed nationwide in the USA.
The recall was issued by the FDA due to lack of assurance of sterility in the recalled syringes. Ketamine HCl Injection is a prescription injectable medication that requires reliable sterilization for safe use.
Healthcare providers and institutions who have received this product should discontinue use and contact Nephron Sterile Compounding Center for information on return and replacement procedures.
The recalled product
- Product
- Ketamine HCl Injection, USP 30 mg/3 mL (10 mg/mL*) syringes, packaged in 5 x 3 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-982-33
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable
- Hazard
- sterility-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: KH2002A
- Exp. 7/5/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01